TW.L vs. GSK.L
Compare and contrast key facts about Taylor Wimpey PLC (TW.L) and GlaxoSmithKline plc (GSK.L).
Performance
TW.L vs. GSK.L - Performance Comparison
Loading graphics...
TW.L vs. GSK.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
TW.L Taylor Wimpey PLC | -17.62% | -3.91% | -11.37% | 57.04% | -36.73% | 11.45% | -4.62% | 58.59% | -28.42% | 44.27% |
GSK.L GlaxoSmithKline plc | 16.41% | 41.46% | -3.51% | 4.94% | -7.40% | 26.74% | -20.72% | 25.38% | 19.09% | -10.77% |
Fundamentals
TW.L:
£3.16B
GSK.L:
£86.09B
TW.L:
£0.09
GSK.L:
£1.39
TW.L:
9.86
GSK.L:
15.11
TW.L:
0.44
GSK.L:
2.64
TW.L:
0.75
GSK.L:
5.26
TW.L:
£7.25B
GSK.L:
£32.67B
TW.L:
£1.31B
GSK.L:
£23.68B
TW.L:
£854.90M
GSK.L:
£11.88B
Returns By Period
In the year-to-date period, TW.L achieves a -17.62% return, which is significantly lower than GSK.L's 16.41% return. Over the past 10 years, TW.L has underperformed GSK.L with an annualized return of 0.33%, while GSK.L has yielded a comparatively higher 8.99% annualized return.
TW.L
- 1D
- 0.00%
- 1M
- -19.64%
- YTD
- -17.62%
- 6M
- -11.36%
- 1Y
- -14.43%
- 3Y*
- -3.01%
- 5Y*
- -7.19%
- 10Y*
- 0.33%
GSK.L
- 1D
- 2.08%
- 1M
- -3.35%
- YTD
- 16.41%
- 6M
- 28.19%
- 1Y
- 49.26%
- 3Y*
- 18.45%
- 5Y*
- 15.08%
- 10Y*
- 8.99%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TW.L vs. GSK.L — Risk / Return Rank
TW.L
GSK.L
TW.L vs. GSK.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Taylor Wimpey PLC (TW.L) and GlaxoSmithKline plc (GSK.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| TW.L | GSK.L | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.49 | 1.85 | -2.34 |
Sortino ratioReturn per unit of downside risk | -0.53 | 2.58 | -3.11 |
Omega ratioGain probability vs. loss probability | 0.94 | 1.34 | -0.40 |
Calmar ratioReturn relative to maximum drawdown | -0.54 | 3.81 | -4.35 |
Martin ratioReturn relative to average drawdown | -1.14 | 9.11 | -10.25 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| TW.L | GSK.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.49 | 1.85 | -2.34 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.25 | 0.69 | -0.94 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.01 | 0.42 | -0.41 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.04 | — | — |
Correlation
The correlation between TW.L and GSK.L is 0.17, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
TW.L vs. GSK.L - Dividend Comparison
TW.L's dividend yield for the trailing twelve months is around 5.26%, more than GSK.L's 3.13% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
TW.L Taylor Wimpey PLC | 8.60% | 8.68% | 7.85% | 6.51% | 8.91% | 4.72% | 8.92% | 9.48% | 11.21% | 6.68% | 7.11% | 4.67% |
GSK.L GlaxoSmithKline plc | 3.13% | 3.51% | 4.53% | 3.84% | 4.69% | 4.98% | 5.96% | 4.50% | 5.36% | 6.05% | 4.93% | 5.83% |
Drawdowns
TW.L vs. GSK.L - Drawdown Comparison
The maximum TW.L drawdown since its inception was -98.99%, smaller than the maximum GSK.L drawdown of -9,894.54%. Use the drawdown chart below to compare losses from any high point for TW.L and GSK.L.
Loading graphics...
Drawdown Indicators
| TW.L | GSK.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.99% | -9,894.54% | +9,795.55% |
Max Drawdown (1Y)Largest decline over 1 year | -27.22% | -13.91% | -13.31% |
Max Drawdown (5Y)Largest decline over 5 years | -52.79% | -27.99% | -24.80% |
Max Drawdown (10Y)Largest decline over 10 years | -56.37% | -30.96% | -25.41% |
Current DrawdownCurrent decline from peak | -41.69% | -9,272.04% | +9,230.35% |
Average DrawdownAverage peak-to-trough decline | -41.98% | -2,430.09% | +2,388.11% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.82% | 5.81% | +7.01% |
Volatility
TW.L vs. GSK.L - Volatility Comparison
Taylor Wimpey PLC (TW.L) has a higher volatility of 9.14% compared to GlaxoSmithKline plc (GSK.L) at 6.51%. This indicates that TW.L's price experiences larger fluctuations and is considered to be riskier than GSK.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| TW.L | GSK.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.14% | 6.51% | +2.63% |
Volatility (6M)Calculated over the trailing 6-month period | 18.76% | 16.85% | +1.91% |
Volatility (1Y)Calculated over the trailing 1-year period | 26.12% | 26.49% | -0.37% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 28.45% | 21.95% | +6.50% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 34.58% | 21.17% | +13.41% |
Financials
TW.L vs. GSK.L - Financials Comparison
This section allows you to compare key financial metrics between Taylor Wimpey PLC and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
TW.L vs. GSK.L - Profitability Comparison
TW.L - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Taylor Wimpey PLC reported a gross profit of 375.90M and revenue of 2.19B. Therefore, the gross margin over that period was 17.2%.
GSK.L - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, GlaxoSmithKline plc reported a gross profit of 5.98B and revenue of 8.62B. Therefore, the gross margin over that period was 69.4%.
TW.L - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Taylor Wimpey PLC reported an operating income of 250.70M and revenue of 2.19B, resulting in an operating margin of 11.5%.
GSK.L - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, GlaxoSmithKline plc reported an operating income of 723.00M and revenue of 8.62B, resulting in an operating margin of 8.4%.
TW.L - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Taylor Wimpey PLC reported a net income of 162.20M and revenue of 2.19B, resulting in a net margin of 7.4%.
GSK.L - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, GlaxoSmithKline plc reported a net income of 636.00M and revenue of 8.62B, resulting in a net margin of 7.4%.